Ultrasound-induced Cavitation enhances the efficacy of Chemotherapy in a 3D Model of Pancreatic Ductal Adenocarcinoma with its microenvironment.
Animals
Carcinoma, Pancreatic Ductal
/ metabolism
Cell Line, Tumor
Deoxycytidine
/ analogs & derivatives
Mice
Mice, Transgenic
Neoplasms, Experimental
/ metabolism
Pancreatic Neoplasms
/ metabolism
Spheroids, Cellular
/ metabolism
Tumor Microenvironment
/ drug effects
Ultrasonic Therapy
Gemcitabine
Pancreatic Neoplasms
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 12 2019
12 12 2019
Historique:
received:
18
07
2019
accepted:
27
11
2019
entrez:
14
12
2019
pubmed:
14
12
2019
medline:
4
11
2020
Statut:
epublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is supported by a complex microenvironment whose physical contribution to chemoresistance could be overcome by ultrasound (US) therapy. This study aims to investigate the ability of US-induced inertial cavitation in association with chemotherapy to alter tumor cell viability via microenvironment disruption. For this purpose, we used a 3D-coculture PDAC model partially mimicking the tumor and its microenvironment. Coculture spheroids combining DT66066 cells isolated from KPC-transgenic mice and murine embryonic fibroblasts (iMEF) were obtained by using a magnetic nanoshuttle method. Spheroids were exposed to US with incremental inertial cavitation indexes. Conditions studied included control, gemcitabine, US-cavitation and US-cavitation + gemcitabine. Spheroid viability was assessed by the reduction of resazurin and flow cytometry. The 3D-coculture spheroid model incorporated activated fibroblasts and produced type 1-collagen, thus providing a partial miniature representation of tumors with their microenvironment. Main findings were: (a) Gemcitabine (5 μM) was significantly less cytotoxic in the presence of KPC/iMEFs spheroids compared with KPC (fibroblast-free) spheroids; (b) US-induced inertial cavitation combined with Gemcitabine significantly decreased spheroid viability compared to Gemcitabine alone; (c) both cavitation and chemotherapy affected KPC cell viability but not that of fibroblasts, confirming the protective role of the latter vis-à-vis tumor cells. Gemcitabine toxicity is enhanced when cocultured spheroids of KPC and iMEF are exposed to US-cavitation. Although the model used is only a partial representation of PDAC, this experience supports the hypothesis that US-inertial cavitation can enhance drug penetration and cytotoxicity by disrupting PDAC microenvironment.
Identifiants
pubmed: 31831785
doi: 10.1038/s41598-019-55388-0
pii: 10.1038/s41598-019-55388-0
pmc: PMC6908636
doi:
Substances chimiques
Deoxycytidine
0W860991D6
Gemcitabine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18916Références
N Engl J Med. 2014 Sep 11;371(11):1039-49
pubmed: 25207767
PLoS One. 2018 Dec 31;13(12):e0209094
pubmed: 30596678
Science. 2009 Jun 12;324(5933):1457-61
pubmed: 19460966
Gastroenterology. 2018 Mar;154(4):820-838
pubmed: 29287624
J Biomol Screen. 2004 Jun;9(4):273-85
pubmed: 15191644
Clin Gastroenterol Hepatol. 2016 Oct;14(10):1452-1462.e4
pubmed: 27266982
Nat Nanotechnol. 2010 Apr;5(4):291-6
pubmed: 20228788
Gastroenterology. 2019 May;156(7):2085-2096
pubmed: 30721663
J Control Release. 2016 Dec 10;243:172-181
pubmed: 27744037
PLoS One. 2015 Jun 08;10(6):e0127948
pubmed: 26053043
Br J Cancer. 2007 Apr 23;96(8):1183-90
pubmed: 17406358
Gastroenterology. 2016 Jun;150(7):1545-1557.e2
pubmed: 27072672
J Vis Exp. 2017 Aug 23;(126):
pubmed: 28872142
Prog Biophys Mol Biol. 2007 Jan-Apr;93(1-3):212-55
pubmed: 16934858
BMC Cancer. 2013 Feb 08;13:73
pubmed: 23394599
Biomaterials. 2016 Nov;108:129-42
pubmed: 27627810
Gut. 2019 Jan;68(1):159-171
pubmed: 30177543
PLoS One. 2013 Sep 10;8(9):e73345
pubmed: 24039920
Int J Exp Pathol. 1998 Feb;79(1):1-23
pubmed: 9614346
Cancer Res. 2001 Jan 15;61(2):550-5
pubmed: 11212248
Cancer Cell. 2005 May;7(5):469-83
pubmed: 15894267
Nat Protoc. 2013 Oct;8(10):1940-9
pubmed: 24030442
Mol Ther. 2010 Jan;18(1):101-8
pubmed: 19623162
Expert Opin Drug Deliv. 2006 Nov;3(6):713-26
pubmed: 17076594
Expert Opin Drug Deliv. 2018 Dec;15(12):1249-1261
pubmed: 30415585
Ultrason Sonochem. 2004 Sep;11(6):349-63
pubmed: 15302020
Theranostics. 2015 Sep 12;5(11):1291-302
pubmed: 26379793
PLoS One. 2015 Aug 14;10(8):e0134247
pubmed: 26274324
J Biotechnol. 2010 Jul 1;148(1):3-15
pubmed: 20097238
Front Physiol. 2012 Aug 28;3:344
pubmed: 22973234
Annu Rev Pathol. 2008;3:157-88
pubmed: 18039136
J Cell Commun Signal. 2011 Aug;5(3):239-48
pubmed: 21499821